Ftse Mib
34.729,20
0,69%
DAX
18.774,71
0,43%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
69.593,94
1,58%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Annovis Bio Inc (ANVS) Annovis Bio Inc (ANVS) Notizie

Annovis Bio Inc

ANVS
7,40
0,32 (4,52%)
25 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
21/5/202422:05EDGAR2Form 8-K - Current report
21/5/202413:30GLOBEAnnovis Announces New Publication in a Peer-Reviewed Journal
13/5/202422:05EDGAR2Form 8-K - Current report
13/5/202413:30GLOBEAnnovis Bio Provides Corporate Updates and Announces First..
10/5/202423:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:03EDGAR2Form 8-K - Current report
09/5/202413:30GLOBEAnnovis Announces Unblinding of the Buntanetap Phase III..
06/5/202423:12EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/5/202423:11EDGAR2Form 8-K - Current report
06/5/202413:30GLOBEAnnovis Bio CEO Maria Maccecchini Issues Letter to..
29/4/202416:10GLOBEAnnovis Bio Announces Statistically Significant Phase II/III..
02/4/202413:30GLOBEAnnovis Bio Provides Corporate Updates and Reports Fourth..
28/2/202413:08IHMARKETNEWSUS Stock Movers Before Market: Beyond Meat, eBay, First..
12/2/202420:00EDGAR2Form S-3/A - Registration statement under Securities Act of..
01/2/202422:05EDGAR2Form S-3 - Registration statement under Securities Act of..
22/11/202322:27EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
21/11/202320:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202320:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202320:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202320:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202322:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202312:30BWAnnovis Bio Measures Novel Biomarkers in Plasma of..
01/11/202317:28EDGAR2Form 8-K - Current report
01/11/202317:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/10/202313:00BWAnnovis Bio Announces Pricing of $7.5 Million Public..
30/10/202322:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/10/202322:17EDGAR2Form 8-K - Current report
30/10/202321:48BWAnnovis Bio Announces Launch of Proposed Public Offering
30/10/202321:42BWAnnovis Bio Receives Positive Recommendation to Continue..
24/10/202315:13BWAnnovis Bio Showcases Promising Progress in Novel Drug..
21/9/202315:35GLOBEDawson James Securities Announces October Date for 8th..
15/8/202313:20BWAnnovis Bio Announces Second Quarter 2023 Financial Results..
14/8/202322:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
18/7/202314:18BWContinued Positive Performance of Novel Drug Development by..
27/6/202313:30BWAnnovis Bio Announces the Filing of a Groundbreaking Patent
20/6/202318:05BWAnnovis Bio Receives Excellent Safety Rating and Positive..
08/6/202313:30PRNUSAnnovis Bio Announces Completion of Phase III Parkinson's..
Apertura: 7,13 Min: 6,91 Max: 7,36
Chiusura: 7,08

La tua Cronologia

NYSE
ANVS
Annovis Bio
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network